All Updates

All Updates

icon
Filter
Funding
BetterLife Pharma raises USD 1.1 million in private placement to advance lead compound
Psychedelic Medicine
Aug 29, 2024
This week:
Management news
6K Additive awarded project to develop C-103 powder for additive manufacturing
Additive Manufacturing
Sep 27, 2024
Partnerships
WAAM3D partners with Innovative Space Carrier, Cranfield University, and Aichi Sangyo for space transport development
Additive Manufacturing
Sep 19, 2024
Product updates
Microsoft launches Face Check with Microsoft Entra Verified ID
Facial Recognition
Sep 11, 2024
Funding
3DEO raises USD 3.5 million in strategic investment from Mizuho Bank
Additive Manufacturing
Sep 6, 2024
Product updates
HyperWrite launches open-source AI model Reflection 70 billion
Generative AI Applications
Sep 5, 2024
Product updates
Google begins US rollout of AI-powered Ask Photos feature
Generative AI Applications
Sep 5, 2024
Funding
Management news
HDAX Therapeutics raises USD 3.2 million in seed funding to progress pipeline and advance preclinical candidates into trials
Precision Medicine
Sep 5, 2024
Partnerships
Sequentify partners with Dexter to expand genomic diagnostics in Romania
Precision Medicine
Sep 5, 2024
Partnerships
Elevate partners with Cultivatd for European expansion
Vertical Farming
Sep 5, 2024
Product updates
Moolec confirms harvest of its genetically engineered plant-grown products
Crop Biotech
Sep 5, 2024
Psychedelic Medicine

Psychedelic Medicine

Aug 29, 2024

BetterLife Pharma raises USD 1.1 million in private placement to advance lead compound

Funding

  • Canadian psychedelic biotechnology company BetterLife Pharma has raised USD 1.1 million via a private placement. The offering consists of units priced at USD 0.15, each comprising one common share and a warrant to purchase one common share at an exercise price of USD 0.20 for up to two years from the date of the closing of the private placement, which is subject to regulatory and other approvals.

  • The new funds will be allocated toward advancing its lead compound, BETR-001, a non-hallucinogenic derivative of lysergic acid diethylamide (LSD), and for general working capital purposes. 

  • Analyst QuickTake: In April 2024 , the company raised USD 74,000 by issuing convertible debentures. This continuous raising of funds underscores BetterLife Pharma's commitment to advancing BETR-001, especially following the FDA's grant of breakthrough therapy designation to MindMed, a psychedelic biotech company, for its LSD-based MM120 program to treat generalized anxiety disorder.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.